Merck, a leading science and technology company, announced today the new startups participating in its Accelerator programs in Darmstadt, Germany and Nairobi, Kenya. The two program locations accept startups from
Tag "Merck"
Regulators on both sides of the Atlantic are reviewing three new submissions for medicines containing ertugliflozin, an investigational SGLT2 inhibitor being developed by Merck and Pfizer to help improve glycaemic
Advertisements
